[
  {
    "ts": null,
    "headline": "Jim Cramer Highlights Eli Lilly’s Drug Potential Beyond Diabetes and Obesity",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer put under the microscope. Cramer highlighted the importance of the company’s GLP-1 drug, as he stated: “I suggest, for example, that you consider Eli Lilly because of its remarkable GLP-1 diabetes and weight loss drug. Those are the most obvious uses. But when […]",
    "url": "https://finnhub.io/api/news?id=e429ca20e63df76f1bb587b0ed049565713d4abfdbd6cc473614fe820cdf1232",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759611715,
      "headline": "Jim Cramer Highlights Eli Lilly’s Drug Potential Beyond Diabetes and Obesity",
      "id": 136980569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer put under the microscope. Cramer highlighted the importance of the company’s GLP-1 drug, as he stated: “I suggest, for example, that you consider Eli Lilly because of its remarkable GLP-1 diabetes and weight loss drug. Those are the most obvious uses. But when […]",
      "url": "https://finnhub.io/api/news?id=e429ca20e63df76f1bb587b0ed049565713d4abfdbd6cc473614fe820cdf1232"
    }
  },
  {
    "ts": null,
    "headline": "Will Caremark’s New Wegovy Copay Program Redefine CVS Health’s (CVS) Approach to Cost and Access?",
    "summary": "In the past week, CVS Health's pharmacy benefit manager Caremark announced a new $200 copay program for Novo Nordisk's weight-loss drug Wegovy, aiming to expand insurance coverage and lower costs for health plans starting in 2026. This move prioritizes Wegovy over Eli Lilly’s Zepbound and could generate multibillion-dollar savings by using negotiated rebates and pricing strategies to benefit both patients and insurers. Caremark’s initiative not only addresses rising drug costs but also...",
    "url": "https://finnhub.io/api/news?id=cc9815161b6d57f578f1dbd0bcda940078868d8fd4e424cda846913ecdc65780",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759586406,
      "headline": "Will Caremark’s New Wegovy Copay Program Redefine CVS Health’s (CVS) Approach to Cost and Access?",
      "id": 136980571,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the past week, CVS Health's pharmacy benefit manager Caremark announced a new $200 copay program for Novo Nordisk's weight-loss drug Wegovy, aiming to expand insurance coverage and lower costs for health plans starting in 2026. This move prioritizes Wegovy over Eli Lilly’s Zepbound and could generate multibillion-dollar savings by using negotiated rebates and pricing strategies to benefit both patients and insurers. Caremark’s initiative not only addresses rising drug costs but also...",
      "url": "https://finnhub.io/api/news?id=cc9815161b6d57f578f1dbd0bcda940078868d8fd4e424cda846913ecdc65780"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: The Bottom Is In",
    "summary": "Discover why NVO offers 20â30% upside with strong EPS growth, sector-leading drugs, and an attractive P/E.",
    "url": "https://finnhub.io/api/news?id=907ea9b7d0425ac2975d8f197528801ce164a83c68a9b012031d747b0696b438",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759565927,
      "headline": "Novo Nordisk: The Bottom Is In",
      "id": 136971549,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1645845625/image_1645845625.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why NVO offers 20â30% upside with strong EPS growth, sector-leading drugs, and an attractive P/E.",
      "url": "https://finnhub.io/api/news?id=907ea9b7d0425ac2975d8f197528801ce164a83c68a9b012031d747b0696b438"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Is Ready for Another Round of the Weight-Loss-Drug Wars",
    "summary": "Barron’s spoke with Dave Moore, executive vice president of U.S. operations, about Wegovy as a pill, rather than an injection.",
    "url": "https://finnhub.io/api/news?id=91c14af65d4b6afde53b6fa40e354caffcb82f968aa6638297a7dadd5f8ce555",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759559400,
      "headline": "Novo Nordisk Is Ready for Another Round of the Weight-Loss-Drug Wars",
      "id": 136980572,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Barron’s spoke with Dave Moore, executive vice president of U.S. operations, about Wegovy as a pill, rather than an injection.",
      "url": "https://finnhub.io/api/news?id=91c14af65d4b6afde53b6fa40e354caffcb82f968aa6638297a7dadd5f8ce555"
    }
  }
]